AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 4076305 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 0
Study 4076305 — intervention group
Group type: COMPARATOR
Intervention: Nondrug conditions in patients with primary degenerative dementia
Number of subjects: 0
Study 30833486 — intervention group
Group type: EXPERIMENTAL
Intervention: Miracle Mouthwash (MMW)
Number of subjects: 100
Study 30833486 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (P)
Number of subjects: 100
Study 30424775 — intervention group
Group type: EXPERIMENTAL
Intervention: Household ownership of LLINs
Number of subjects: 5196
Study 30424775 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate LLIN coverage
Number of subjects: 5196
Study 30424775 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of LLINs
Number of subjects: 5196
Study 29952189 — intervention group
Group type: EXPERIMENTAL
Intervention: PLF with local bone graft with BM concentrate augmentation (BM group)
Number of subjects: 12
Study 29952189 — intervention group
Group type: COMPARATOR
Intervention: PLF with local bone graft only (non‐BM group)
Number of subjects: 12
Study 29952189 — intervention group
Group type: EXPERIMENTAL
Intervention: BM group
Number of subjects: 12
Study 29952189 — intervention group
Group type: COMPARATOR
Intervention: non‐BM group
Number of subjects: 12
Study 25244442 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg/day
Number of subjects: 115
Study 25244442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 22714033 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal indomethacin (100 mg suppository)
Number of subjects: 228
Study 22714033 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inert suppository)
Number of subjects: 228
Study 20662716 — intervention group
Group type: EXPERIMENTAL
Intervention: Replication-defective adenovirus type 5 HIV-1 gag vaccine
Number of subjects: 0
Study 20662716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16870842 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory threshold loading
Number of subjects: 6
Study 16244523 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 degrees lateral wedge
Number of subjects: 50
Study 16244523 — intervention group
Group type: COMPARATOR
Intervention: 0 degrees control wedge
Number of subjects: 50
Study 12172314 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 66
Study 12172314 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 66
Study 12172314 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-recorded BP
Number of subjects: 66
Study 12172314 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h ambulatory BP
Number of subjects: 66
Study 12172314 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal ambulatory BP
Number of subjects: 66
Study 9549819 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative treatment in advanced cancer
Number of subjects: 0
Study 9549819 — intervention group
Group type: EXPERIMENTAL
Intervention: Imputation of missing QOL data based on auxiliary outcome variables
Number of subjects: 0
Study 9549819 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventative strategies in trial design
Number of subjects: 0
Study 9549819 — intervention group
Group type: EXPERIMENTAL
Intervention: Collection of auxiliary QOL information
Number of subjects: 0
Study 7605708 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-bearing exercise (50 'heel drops' daily and weekly mixed exercise class)
Number of subjects: 44
Study 7605708 — intervention group
Group type: COMPARATOR
Intervention: Control group (weekly low-impact exercise class and daily flexibility exercises)
Number of subjects: 44
Study 2178854 — intervention group
Group type: COMPARATOR
Intervention: 150 mg ranitidine (single dose)
Number of subjects: 12
Study 2178854 — intervention group
Group type: COMPARATOR
Intervention: 150 mg ranitidine (multiple doses, b.i.d. for 7 days)
Number of subjects: 12
Study 2178854 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (7 days treatment)
Number of subjects: 12
Study 6994824 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal EMG biofeedback and progressive relaxation training for 15 weeks
Number of subjects: 20
Study 6994824 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 31577041 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) gel treatment for 45 days
Number of subjects: 54
Study 31577041 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HA treatment)
Number of subjects: 54
Study 30741701 — intervention group
Group type: EXPERIMENTAL
Intervention: Training serial button-press motor task (SPMT), 5 days a week for two consecutive weeks
Number of subjects: 20
Study 30741701 — intervention group
Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 20
Study 28673527 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention (BMI)
Number of subjects: 530
Study 28673527 — intervention group
Group type: COMPARATOR
Intervention: Assessment Only (AO)
Number of subjects: 530
Study 23294942 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alteplase
Number of subjects: 1000
Study 23604998 — intervention group
Group type: EXPERIMENTAL
Intervention: High-load resistance exercise (n=22)
Number of subjects: 62
Study 23604998 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load resistance exercise (n=21)
Number of subjects: 62
Study 23604998 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=19)
Number of subjects: 62
Study 21819517 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro protamine suspension (ILPS)
Number of subjects: 383
Study 21819517 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 383
Study 19683429 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Number of subjects: 0
Study 17881751 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat courses of antenatal corticosteroids (betamethasone, 12 mg intramuscularly, repeated once at 24 hours)
Number of subjects: 556
Study 17881751 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical-appearing)
Number of subjects: 556
Study 17881751 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat courses of antenatal corticosteroids
Number of subjects: 556
Study 17881751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 556
Study 15089812 — intervention group
Group type: EXPERIMENTAL
Intervention: St John's wort
Number of subjects: 12
Study 15089812 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginseng
Number of subjects: 12
Study 15089812 — intervention group
Group type: COMPARATOR
Intervention: Warfarin alone
Number of subjects: 12
Study 11347790 — intervention group
Group type: EXPERIMENTAL
Intervention: Training intervention (14-hour program in seven weekly 2-hour sessions)
Number of subjects: 94
Study 11347790 — intervention group
Group type: EXPERIMENTAL
Intervention: Training intervention
Number of subjects: 94
Study 11347790 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 94
Study 9783563 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clomipramine (starting at 25 mg/d and increasing to 250 mg/d)
Number of subjects: 54
Study 9783563 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clomipramine (initially randomized to i.v. clomipramine and treated subsequently with oral clomipramine)
Number of subjects: 54
Study 9783563 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo (initially randomized to receive i.v. placebo and treated subsequently with several days of open-label i.v. clomipramine)
Number of subjects: 54
Study 9783563 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clomipramine (1 month after i.v. infusion)
Number of subjects: 54
Study 7945519 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen lysinate (IBL) 800 mg/d
Number of subjects: 45
Study 7945519 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 2000 mg/d
Number of subjects: 45
Study 7945519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 3604740 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 60
Study 3604740 — intervention group
Group type: COMPARATOR
Intervention: Oxazepam
Number of subjects: 60
Study 29258336 — intervention group
Group type: EXPERIMENTAL
Intervention: Chickpea-based RUTF
Number of subjects: 30
Study 29258336 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice-lentil-based RUTF
Number of subjects: 30
Study 29258336 — intervention group
Group type: COMPARATOR
Intervention: Prototype RUTF (Plumpy'Nut)
Number of subjects: 30
Study 28215117 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental stretching program
Number of subjects: 94
Study 28215117 — intervention group
Group type: COMPARATOR
Intervention: Observation group
Number of subjects: 94
Study 26323772 — intervention group
Group type: EXPERIMENTAL
Intervention: Bench step exercise for 16 weeks
Number of subjects: 13
Study 26323772 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 13
Study 23914766 — intervention group
Group type: EXPERIMENTAL
Intervention: Compassion induction
Number of subjects: 0
Study 23914766 — intervention group
Group type: COMPARATOR
Intervention: Neutral induction
Number of subjects: 0
Study 20940102 — intervention group
Group type: COMPARATOR
Intervention: Whole Body Vibration (WBV)
Number of subjects: 9
Study 20940102 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal Voluntary Contractions (MVC)
Number of subjects: 9
Study 20940102 — intervention group
Group type: EXPERIMENTAL
Intervention: MVC alternated with WBV (MVC-WBV)
Number of subjects: 9
Study 19317165 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Tongdu Decoction (BTD)
Number of subjects: 75
Study 19317165 — intervention group
Group type: COMPARATOR
Intervention: Azulfidine
Number of subjects: 75
Study 19317165 — intervention group
Group type: COMPARATOR
Intervention: Normal control (30 healthy persons)
Number of subjects: 75
Study 16015665 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine hydrochloride (CH) 4 mg up to four times a day
Number of subjects: 12
Study 16015665 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine hydrochloride (CH) continued from the short-term study
Number of subjects: 12
Study 16015665 — intervention group
Group type: COMPARATOR
Intervention: Placebo (original short-term study)
Number of subjects: 12
Study 16015665 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine hydrochloride (CH)
Number of subjects: 12
Study 12937950 — intervention group
Group type: EXPERIMENTAL
Intervention: Image fusion between FDG-PET and CT
Number of subjects: 32
Study 10383550 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan 500 mg twice daily for 1 week
Number of subjects: 18
Study 10383550 — intervention group
Group type: COMPARATOR
Intervention: Digoxin 0.375 mg once daily for 13 days
Number of subjects: 18
Study 8720227 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop-steroid group (19 patients)
Number of subjects: 89
Study 8720227 — intervention group
Group type: COMPARATOR
Intervention: No-steroid group (70 patients)
Number of subjects: 89
Study 1879030 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet cucumber vine compound
Number of subjects: 389
Study 1879030 — intervention group
Group type: COMPARATOR
Intervention: Tablet hypotension compound (Control)
Number of subjects: 389
Study 7106164 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide 5.0 mg solution
Number of subjects: 0
Study 7106164 — intervention group
Group type: COMPARATOR
Intervention: Indapamide 2.5 mg tablets
Number of subjects: 0
Study 7106164 — intervention group
Group type: EXPERIMENTAL
Intervention: All formulations
Number of subjects: 0
Study 31927028 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg
Number of subjects: 121
Study 31927028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 31083767 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoke Free smartphone application
Number of subjects: 4990
Study 31083767 — intervention group
Group type: COMPARATOR
Intervention: No support (control)
Number of subjects: 4990
Study 27662113 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (1.5 mA)
Number of subjects: 37
Study 26503370 — intervention group
Group type: EXPERIMENTAL
Intervention: New training model
Number of subjects: 77
Study 26503370 — intervention group
Group type: COMPARATOR
Intervention: Old training model
Number of subjects: 77
Study 23317171 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 deficiency patients
Number of subjects: 45
Study 23317171 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 45
Study 21598183 — intervention group
Group type: EXPERIMENTAL
Intervention: Water clubs
Number of subjects: 0
Study 21598183 — intervention group
Group type: COMPARATOR
Intervention: Water and control clubs
Number of subjects: 0
Study 19540518 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide, 0.2 mg/kg/dose q 6 hours
Number of subjects: 18
Study 19540518 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine, 2 mg/kg/dose q 8 hours
Number of subjects: 18
Study 19540518 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 18
Study 17296386 — intervention group
Group type: EXPERIMENTAL
Intervention: Video endoscopic inguinal lymphadenectomy
Number of subjects: 10
Study 17296386 — intervention group
Group type: COMPARATOR
Intervention: Standard inguinal lymphadenectomy
Number of subjects: 10
Study 15385355 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg of rocuronium based on real body weight (Group 1)
Number of subjects: 12
Study 15385355 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg of rocuronium based on ideal body weight (Group 2)
Number of subjects: 12
Study 15385355 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium dosed based on real body weight in normal-weight female patients (Control group)
Number of subjects: 12
Study 11481696 — intervention group
Group type: EXPERIMENTAL
Intervention: Idazoxan 20 mg
Number of subjects: 18
Study 11481696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9755345 — intervention group
Group type: EXPERIMENTAL
Intervention: diet‐plus‐exercise program
Number of subjects: 177
Study 9755345 — intervention group
Group type: COMPARATOR
Intervention: diet‐only program
Number of subjects: 177
Study 9755345 — intervention group
Group type: EXPERIMENTAL
Intervention: diet‐plus‐exercise program (dissatisfied participants)
Number of subjects: 177
Study 8110564 — intervention group
Group type: COMPARATOR
Intervention: i.v. fluids (preloading with normal saline 16 ml kg‐1 and, if necessary, three subsequent boluses of 2.5 ml kg‐1)
Number of subjects: 34
Study 8110564 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaraminol infusion titrated between 0 and 5 mg h‐1
Number of subjects: 34
Study 8110564 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine infusion titrated between 0 and 120 mg h‐1
Number of subjects: 34
Study 3288007 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine aerosol
Number of subjects: 30
Study 3288007 — intervention group
Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 30
Study 3288007 — intervention group
Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 30
Study 30425166 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric cough mode (VCM)
Number of subjects: 20
Study 30425166 — intervention group
Group type: COMPARATOR
Intervention: Breath-stacking
Number of subjects: 20
Study 30425166 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 20
Study 28784453 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial perfusion scintigraphy (MPS)
Number of subjects: 400
Study 25034199 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain Language Summary (PLS)
Number of subjects: 143
Study 25034199 — intervention group
Group type: COMPARATOR
Intervention: Current format used in Cochrane systematic reviews (Control)
Number of subjects: 143
Study 22732767 — intervention group
Group type: COMPARATOR
Intervention: lumiracoxib
Number of subjects: 6
Study 21906457 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (3 mg)
Number of subjects: 200
Study 21906457 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron (4 mg)
Number of subjects: 200
Study 19106862 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic dilatation
Number of subjects: 0
Study 19106862 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Heller cardiomyotomy
Number of subjects: 0
Study 19106862 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended esophageal myotomy
Number of subjects: 0
Study 17238677 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic alert
Number of subjects: 0
Study 17238677 — intervention group
Group type: COMPARATOR
Intervention: Control group (no electronic alert)
Number of subjects: 0
Study 14983966 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate cancer screening with prostate-specific antigen (PSA)
Number of subjects: 0
Study 11186221 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 0
Study 11186221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8694322 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% (40 mL)
Number of subjects: 41
Study 8694322 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%, 40 mL)
Number of subjects: 41
Study 1348167 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium repeated injection
Number of subjects: 40
Study 1348167 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium infusion
Number of subjects: 40
Study 1348167 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium repeated injection
Number of subjects: 40
Study 1348167 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium infusion
Number of subjects: 40
Study 1348167 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (7 micrograms/kg)
Number of subjects: 40
Study 4003624 — intervention group
Group type: EXPERIMENTAL
Intervention: BSE group education session
Number of subjects: 0
Study 31939368 — intervention group
Group type: EXPERIMENTAL
Intervention: Mtwo files
Number of subjects: 30
Study 31939368 — intervention group
Group type: COMPARATOR
Intervention: H‐files
Number of subjects: 30
Study 28329315 — intervention group
Group type: EXPERIMENTAL
Intervention: Macitentan
Number of subjects: 187
Study 28329315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 28391664 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract tablets (0.7 g, 0.05% green tea extract, equivalent to 1 mg polyphenols for three tablets)
Number of subjects: 54
Study 28391664 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets (identical to test tablets but without active agent)
Number of subjects: 54
Study 24628987 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited ablation (CFAE: <60 milliseconds)
Number of subjects: 90
Study 24628987 — intervention group
Group type: COMPARATOR
Intervention: Extensive ablation (CFAE: <120 milliseconds)
Number of subjects: 90
Study 24628987 — intervention group
Group type: EXPERIMENTAL
Intervention: Both limited and extensive approaches
Number of subjects: 90
Study 24628987 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited ablation
Number of subjects: 90
Study 20924095 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacy service (CPS)
Number of subjects: 300
Study 20924095 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (control)
Number of subjects: 300
Study 20108208 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet C (increased consumption of cereals, some enriched with vitamin D)
Number of subjects: 61
Study 20108208 — intervention group
Group type: COMPARATOR
Intervention: Diet V (increased consumption of greens and vegetables)
Number of subjects: 61
Study 17514726 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary breaks (two 15 min breaks plus four 5 min breaks per day)
Number of subjects: 51
Study 17514726 — intervention group
Group type: COMPARATOR
Intervention: Stretching exercises during breaks
Number of subjects: 51
Study 17514726 — intervention group
Group type: COMPARATOR
Intervention: Conventional breaks (two 15 min breaks per day)
Number of subjects: 51
Study 15087592 — intervention group
Group type: EXPERIMENTAL
Intervention: Shower PUVA with trioxsalen (0.27 mg/l) for 10 min
Number of subjects: 20
Study 15087592 — intervention group
Group type: EXPERIMENTAL
Intervention: Shower PUVA with trioxsalen (0.27 mg/l) for 5 min
Number of subjects: 20
Study 12409965 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat plus diet
Number of subjects: 0
Study 12409965 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus diet
Number of subjects: 0
Study 9855321 — intervention group
Group type: EXPERIMENTAL
Intervention: valspodar 400 mg
Number of subjects: 18
Study 9855321 — intervention group
Group type: EXPERIMENTAL
Intervention: dexamethasone 8 mg
Number of subjects: 18
Study 9855321 — intervention group
Group type: EXPERIMENTAL
Intervention: both drugs concomitantly
Number of subjects: 18
Study 7738215 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent famotidine (20 mg every 12 hr)
Number of subjects: 6
Study 7738215 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of cimetidine (1200 mg/24 hr)
Number of subjects: 6
Study 7738215 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of ranitidine (150 mg/24 hr)
Number of subjects: 6
Study 7738215 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of famotidine (40 mg/24 hr)
Number of subjects: 6
Study 2973343 — intervention group
Group type: EXPERIMENTAL
Intervention: Polytetrafluoroethylene (PTFE)
Number of subjects: 80
Study 2973343 — intervention group
Group type: COMPARATOR
Intervention: Dacron
Number of subjects: 80
Study 2973343 — intervention group
Group type: EXPERIMENTAL
Intervention: PTFE
Number of subjects: 80
Study 4925077 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% idoxuridine in dimethyl sulphoxide intermittently applied
Number of subjects: 0
Study 4925077 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% idoxuridine in dimethyl sulphoxide continuously applied for four days
Number of subjects: 0
Study 31797570 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic prucalopride tablets
Number of subjects: 12